Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.30 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010620 | 0.87 | AR (0.38) | ARCHRNB2CHRNA4CDC7CHRNA7 | |
| SCHEMBL1615703 | 0.83 | CDC7 (0.38) | ADORA3ADORA2AADORA1CHRNB2CHRNA4 | |
| SCHEMBL24090522 | 0.77 | AR (0.40) | AR | |
| SCHEMBL18886131 | 0.77 | AR (0.40) | AR | |
| SCHEMBL26620749 | 0.77 | CHRNB2 (0.34) | ARADORA3ADORA2AADORA1CHRNB2 | |
| SCHEMBL13059131 | 0.77 | AR (0.40) | AR | |
| SCHEMBL24316223 | 0.73 | AR (0.43) | ARCHRNB2CHRNA4ALDH1A1MAPT | |
| SCHEMBL10297581 | 0.72 | SIGMAR1 (0.38) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL25516801 | 0.72 | SIGMAR1 (0.38) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL13656199 | 0.72 | AR (0.42) | ARCHRNB2CHRNA4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | AR 2205/4885ADORA3 3544/4885ADORA2A 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.